| Serial Number | 90696853 |
| Word Mark | REVERSIR |
| Filing Date | Friday, May 7, 2021 |
| Status | 605 - ABANDONED - EXPRESS AFTER PUB |
| Status Date | Tuesday, March 29, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 25, 2022 |
| Goods and Services | Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection |
| Pseudo Mark | REVERSER |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 8 - Abandoned |
| Class Status Date | Tuesday, March 29, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Alnylam Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02142 |
| Party Name | Alnylam Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02142 |
| Event Date | Event Description |
| Wednesday, March 30, 2022 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION |
| Tuesday, March 29, 2022 | ABANDONMENT - AFTER PUBLICATION |
| Wednesday, March 23, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, March 23, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, March 23, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, March 23, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, March 23, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, March 23, 2022 | TEAS EXPRESS ABANDONMENT RECEIVED |
| Wednesday, February 16, 2022 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, January 25, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 25, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 5, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Saturday, December 18, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Saturday, December 18, 2021 | ASSIGNED TO EXAMINER |
| Monday, August 9, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, May 11, 2021 | NEW APPLICATION ENTERED IN TRAM |